Dycloninum [INN-Latin] en es it fr

Dycloninum [INN-Latin] Brand names, Dycloninum [INN-Latin] Analogs

Dycloninum [INN-Latin] Brand Names Mixture

  • No information avaliable

Dycloninum [INN-Latin] Chemical_Formula


Dycloninum [INN-Latin] RX_link


Dycloninum [INN-Latin] fda sheet

Dycloninum_[INN-Latin] FDA

Dycloninum [INN-Latin] msds (material safety sheet)

Dycloninum [INN-Latin] Synthesis Reference

No information avaliable

Dycloninum [INN-Latin] Molecular Weight

382.52 g/mol

Dycloninum [INN-Latin] Melting Point

No information avaliable

Dycloninum [INN-Latin] H2O Solubility

Readily soluble as hydrobromide formulation

Dycloninum [INN-Latin] State


Dycloninum [INN-Latin] LogP


Dycloninum [INN-Latin] Dosage Forms

Tablet for oral administration (24.2 or 48.5 mg)

Dycloninum [INN-Latin] Indication

For the acute treatment of migraine with or without aura in adults.

Dycloninum [INN-Latin] Pharmacology

Eletriptan is a selective 5-hydroxytryptamine 1B/1D receptor agonist. In the anesthetized dog, eletriptan has been shown to reduce carotid arterial blood flow, with only a small increase in arterial blood pressure at high doses. While the effect on blood flow was selective for the carotid arterial bed, decreases in coronary artery diameter were observed. Eletriptan has also been shown to inhibit trigeminal nerve activity in the rat.

Dycloninum [INN-Latin] Absorption

Well absorbed after oral administration with a mean absolute bioavailability of approximately 50%.

Dycloninum [INN-Latin] side effects and Toxicity

Based on the pharmacology of the 5-HT1B/1D agonists, hypertension or other more serious cardiovascular symptoms could occur on overdose.

Dycloninum [INN-Latin] Patient Information

No information avaliable

Dycloninum [INN-Latin] Organisms Affected

Humans and other mammals